Replies to post #13531 on RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

Aiming,

I think Stoll made it clear that he is only going to be licensing molecules, not indications.


Bladerunner

[atheroprevent]

<<Of course this all hinges on how the RD trial turns out>>

If RD indication is viable, SA will be the next target. SA is growing in proportion to the epidemic of obesity and is treatable largely with CPAP. No suitable drug therapy is available. An ampakine stimulated respiratory drive might provide a more acceptable therapy. A few patients could be run in 2008 on COR's budget for proof of concept. SA = 10 x RD potential.

In this scenario AD + ADHD would not be needed to pull Cor out of the FDA induced quagmire.